Tag: ARDS

1. Tocilizumab was not superior to standard care after 15 days, for COVID-19 patients in serious condition. 2. Patients given tocilizumab had higher rates of mortality and adverse events, but shorter hospital stays compared to the standard care group. Evidence Rating Level: 1 (Excellent) Study rundown: The COVID-19 pandemic has resulted in...
1. In this small, uncontrolled, non-randomized case series, clinical improvement was noted in 5 critically ill patients with COVID-19 and ARDS following treatment with convalescent plasma. Evidence Rating: 4 (Below Average) With no specific therapeutic agents or vaccines available for COVID-19, ongoing efforts are being made to identify a treatment option...
1. In-hospital COVID-19-related death was associated with older age, d-dimer levels greater than 1.0μg/mL, and higher Sequential Organ Failure Assessment upon assessment. 2. Median viral shedding in survivors was 20 days but was present until death in fatal cases. 3. Hypertension, diabetes, and coronary artery disease were the most common comorbidities in the...
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 1. SARS-CoV-2 appears to have the longest surface viability on plastic and stainless steel compared to in aerosol, copper, or cardboard with detection of viable virus up to 72 hours post application on plastic. 2. Stability of SARS-CoV-2 appears to similar...
1. Children of all ages were susceptible to SARS-CoV-2 infection, with infants and younger children being most at risk for severe and critical illness. There was only 1 death reported. 2. Across all age groups, 94% of children had asymptomatic, mild, or moderate illness. 5% had severe illness, and <1%...
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial 1. Study findings suggest that early administration of intravenous dexamethasone during acute respiratory distress syndrome may decrease duration of mechanical ventilation and mortality rates. Evidence Level: 1 (Excellent) Acute respiratory distress syndrome (ARDS), characterized by acute hypoxemic respiratory failure...
1. Among at-risk patients in the emergency department, administration of aspirin within 24 hours of presentation was not associated with a reduction in the incidence of acute respiratory distress syndrome (ARDS). Evidence Rating Level: 2 (Good)        Study Rundown: ARDS, characterized by the rapid development of respiratory failure, is...
Classics Series, Landmark Trials in Medicine
1. In patients with severe acute respiratory distress syndrome (ARDS), prone-positioning significantly reduced 28-day and 90-day mortality when compared with patients remaining in supine position. 2. Proned patients were also successfully extubated at higher rates and required fewer days of ventilation when compared to supine patients. Original Date of Publication: June...
Classics Series, Landmark Trials in Medicine
1. In patients with severe acute respiratory distress syndrome (ARDS), treatment with neuromuscular blockade in the first 48 hours significantly reduced 90-day and 28-day mortality when compared to placebo. 2. The group treated with the neuromuscular blocker also experienced significantly lower rates of barotrauma and there were no differences between...
1. When compared with placebo, simvastatin did not significantly reduce the number of ventilator-free days in patients presenting with acute respiratory distress syndrome. 2. Moreover, simvastatin did not significantly reduce 28-day mortality as compared with placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Acute respiratory distress syndrome (ARDS) refers to a spectrum...